Compare STEX & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STEX | KZIA |
|---|---|---|
| Founded | 2009 | 1994 |
| Country | United States | Australia |
| Employees | 6 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.3M | 100.8M |
| IPO Year | N/A | 2002 |
| Metric | STEX | KZIA |
|---|---|---|
| Price | $0.80 | $14.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $9.00 | ★ $19.50 |
| AVG Volume (30 Days) | ★ 1.4M | 182.2K |
| Earning Date | 05-17-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,044.81 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.70 | $4.86 |
| 52 Week High | $7.44 | $17.40 |
| Indicator | STEX | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 38.96 | 59.82 |
| Support Level | $0.70 | $5.62 |
| Resistance Level | $1.12 | $14.57 |
| Average True Range (ATR) | 0.10 | 1.08 |
| MACD | -0.03 | 0.14 |
| Stochastic Oscillator | 21.74 | 81.64 |
Streamex Corp is a vertically integrated technology and infrastructure company. The Company is a technology company with two principal lines of business: (i) Tokenized Asset Finance, focused on digital asset and real-world asset tokenization via Streamex Exchange platform, and (ii) Biomedical Technology, focused on signal processing solutions in electrophysiology. The group provides institutional-grade solutions that bring traditional commodities and assets on-chain through secure, regulated, and yield-bearing financial instruments. It is committed to delivering transparent, scalable, and compliant digital asset solutions that bridge the gap between traditional finance and blockchain-enabled markets.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.